Ofatumumab support treatment seems to delay movement free endurance (PFS) in patients with backslid constant lymphocytic leukemia (CLL), as indicated by conclusive outcomes from the PROLONG study (ClinicalTrials.gov Identifier: NCT01039376) distributed in Blood Cancer Journal. Delay was a global, multicenter, open-name, randomized, stage 3 investigation on ofatumumab upkeep in patients with CLL in complete abatement […]
